



## **SYNTHESIS AND CHARACTERIZATION OF N-MANNICH BASES WITH PYRIMETHAMINE FOR ANTIMICROBIAL ACTIVITIES**

**M. SENTHILRAJA\* and S. ANAND THANGADHURAI**

\*Department of Pharmaceutical Chemistry,  
Cherraan's College of Pharmacy, COIMBATORE – 641 039 (T.N.) INDIA  
and

Department of Pharmaceutical Chemistry,  
Nandha College of Pharmacy, ERODE – 683 052 (T.N.) INDIA

### **ABSTRACT**

Schiff bases of isatin with pyrimethamine and its N-Mannich bases were synthesized. Their chemical structures have been confirmed by UV, IR and <sup>1</sup>H NMR data. Antimicrobial evaluation was done by agar dilution method against 10 pathogenic bacteria and 4 pathogenic fungi. The new derivatives exhibited higher potency compared to the standard drugs against all organisms (against all bacteria). All the compounds exhibited antifungal activity.

**Key word :** Antimicrobial activity, N-Mannich bases, Pyrimethamine

### **INTRODUCTION**

Several Schiff and N-Mannich bases of isatin derivatives possessed marked antibacterial, antifungal and anti-HIV activities<sup>1-5</sup>. Synthesis of some new compounds of N-Mannich bases using isatin with pyrimethamine for antibacterial and antifungal activities are reported herein. The Schiff base, (3-pyrimethyminylimino isatin) was prepared by the reaction of isatin with pyrimethamine in presence of glacial acetic acid. The N-Mannich bases (PM<sub>2</sub>-PM<sub>6</sub>) of the above Schiff bases were prepared by condensing with formaldehyde and secondary amines. The structure of all the new compounds were confirmed by their UV, IR and <sup>1</sup>H NMR spectra and elemental analysis. All the synthesized compounds have screened for antibacterial and antifungal activity by agar dilution method.

### **EXPERIMENTAL**

The melting points were determined using capillary tube method and are uncorrected. The UV, IR and NMR spectra were recorded on a Shimadzu 1601 Model Shimadzu, FTIR (KB) and JEOL FX 90 QFT – NMR (90 MHz) instruments, respectively.

---

\*Corresponding author

### Synthesis of 2-(3''-isatinimino)-5-(4'-chlorophenyl)-6-ethyl-4-minopyrimidine (PM<sub>1</sub>)

Equimolar quantities (0.05 mol) of isatin (7.55 g) and pyrimethamine (12.55 g) were dissolved in ethanol (75 mL) and 2–3 drops of glacial acetic acid. The reaction mixture was refluxed for 4 hours and set aside. The precipitate was filtered, washed with ethanol and dried. Recrystallisation using ethanol: chloroform mixture yield 71.86%; m.p. 186 – 190°C; UV (CH<sub>3</sub>OH),  $\lambda_{\max}$  270.5 nm; IR (KBr): 3300 (NH), 1659 (C=O), 1578 (C=N) cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  ppm: 0.98 (3H, CH<sub>3</sub> of C<sub>2</sub>H<sub>5</sub>), 2.2 (2H of CH<sub>2</sub> of C<sub>2</sub>H<sub>5</sub>) 5.4 (2H, NH<sub>2</sub>), 6.8 – 7.2 (m, 8H, Ar – H), 10.4 (s, 1H, NH); Mol. formula is C<sub>20</sub> H<sub>16</sub> N<sub>5</sub> OCl.

### Synthesis of 2-(1''-N, N-diphenylamino) methyl-3''-isatinimino)-5-(4'-chlorophenyl)-6-ethyl-4-aminopyrimidine (PM<sub>2</sub>)

The PM<sub>1</sub> (0.003 mol.) step product was dissolved in ethanol (5 mL), 37% Formaldehyde (1.5 mL). To this mixture, 5 mL of N, N-diphenylamine was added dropwise with rigorous stirring and allowed to stand at room temperature for 1 hour with occasional shaking. It was warmed on a water bath for 20 minutes, cooled and the product was filtered. Recrystallization using chloroform – petroleum ether (1:1) mixture yield : 54.90%; m.p: 131 – 135°C; UV (CHCl<sub>3</sub>),  $\lambda_{\max}$  273.5 nm; IR (KBr) 2970, 2800 (CH of CH<sub>3</sub>), 2860 (CH of CH<sub>2</sub>), 1659 (C=O), 1578 (C=N) <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  ppm: 0.98 (3H, CH<sub>3</sub> of C<sub>2</sub>H<sub>5</sub>), 2.1 (2H, CH<sub>2</sub> of C<sub>2</sub>H<sub>5</sub>), 2.2 (10H, s, N (C<sub>6</sub>H<sub>5</sub>)<sub>2</sub>); 4.89 (2H, N-CH<sub>2</sub>-N) 6.8– 7.2 (m. 6H, Ar- H); Mol formula : C<sub>33</sub> H<sub>27</sub> N<sub>6</sub> OCl. The physical constants of the title compounds are represented in Table –1.

**Table 1. Physical constant of the synthesized compounds**

Compound	Yield (%)	M.P. (°C)	Molecular formula	Molecular weight	R <sub>f</sub> value
PM <sub>1</sub>	71	188	C <sub>20</sub> H <sub>16</sub> N <sub>5</sub> OCl	377	0.77
PM <sub>2</sub>	54	133	C <sub>33</sub> H <sub>27</sub> N <sub>6</sub> OCl	558	0.67
PM <sub>3</sub>	61	137	C <sub>25</sub> H <sub>25</sub> N <sub>7</sub> OCl	474	0.59
PM <sub>4</sub>	59	128	C <sub>26</sub> H <sub>23</sub> N <sub>6</sub> OCl	470	0.59
PM <sub>5</sub>	60	127	C <sub>26</sub> H <sub>25</sub> N <sub>7</sub> OCl	486	0.63
PM <sub>6</sub>	52	112	C <sub>32</sub> H <sub>27</sub> N <sub>8</sub> O <sub>3</sub> Cl	606	0.54

\* Eluent used in TLC was CHCl<sub>3</sub> : CH<sub>3</sub>OH : Ammonia in 7:2:1 ratio.

### ANTIBACTERIAL ACTIVITY

The antibacterial activity was determined by agar dilution method against 10 pathogenic bacteria, procured from microbiological laboratory. The medium was prepared as per the



instruction of the manufacturer of dry Muller–Hinton agar powder (Hi Media). The concentration of the test samples used were from lower concentration to 5000 mcg/ mL made by serial dilutions with dimethylformamide. The minimum inhibitory concentration (MIC) was taken as the lowest concentration (higher dilution) without visible growth. The study was also simultaneously performed for the pure standard drugs (Norfloxacin and pyrimethamine). The MIC<sub>s</sub> are reported in Table–2.

**Table 2. Minimum inhibitory concentrations of synthesized compounds**

Micro Organism/Drug	PM <sub>1</sub>	PM <sub>2</sub>	PM <sub>3</sub>	PM <sub>4</sub>	PM <sub>5</sub>	PM <sub>6</sub>	Pyrimethamine	Norfloxacin
Bacillus subtilis	100	50	100	150	300	150	1250	150
Staphylococcus aureus	50	75	50	100	300	50	2500	300
E. coli	1500	1000	150	1500	2500	1000	2500	625
Samonella paratyphi - A	50	500	50	750	500	40	2500	625
Shigella boydii	300	500	50	250	250	50	> 2500	125
Vibrio parahaemolyticus	150	625	150	2500	1250	50	5000	300
Shigella dysenteriae	200	625	300	5000	5000	625	2500	50
Pseudomonas aeruginosa	> 5000	100	150	625	5000	500	> 5000	10
Staphylococcus albus	50	625	100	1250	> 5000	100	2500	300
Glebsela. pneumoneae	1250	625	100	> 5000	1250	150	> 5000	300

MICs of the compound in µg/µL.

### ANTIFUNGAL ACTIVITY

Five compounds were screened for antifungal activity by agar dilution method at a concentration of 200 mcg/mL against 4 pathogenic fungi. The compounds were soluble in DMF.

### RESULTS AND DISCUSSION

All the compounds showed a marked variety against microorganism. The MICs of the compounds against 10 pathogenic bacteria are presented in Table 2. Also included are the activity of Pyrimethamine and Norfloxacin. All the N–Mannich bases (PM<sub>2</sub> – PM<sub>6</sub>) were more potent than Pyrimethamine. The compound PM<sub>1</sub> and PM<sub>6</sub> were more potent than Norfloxacin against Vibrio parahaemolyticus. The compounds PM<sub>3</sub> is more potent than Norfloxacin against Bacillus substilis, Staphylococcus aureus, Shigella boydii, Vibrio parahaemolyticus and Klebsela pneumonea and PM<sub>1</sub> was found to be inactive against Pseudomonas species. The most active in this series was piperazinyl derivatives (PM<sub>3</sub>) and sulphopyridyl derivatives (PM<sub>6</sub>) with MIC of 40 mcg and 50 mcg/mL against Staphylococcus aureus, Salmonella paratyphi

*Shigella boydii*, *Vibrio parahaemolyticus*, *Shigella dysenteriae*, *Staphylococcus albus* and *Glebsela pneumoneae*.

In the antifungal testing, the compounds (PM<sub>3</sub> – PM<sub>6</sub>) showed activity at 100 µg/µL against *Canida albicans*, *Cryptococcus neoformans*, *Histoplasma capsulatum* and *Trichophyton menagophytes*.

### ACKNOWLEDGEMENT

Sincere thanks of the authors are due to Department of Pharmaceutical Chemistry, Cherraan's College of Pharmacy for providing necessary facilities to carry out this work.

### REFERENCES

1. S. N. Pandeya, P. Yogeewari, D. Sriram and G. Nath, *Boll. Chim. Farm.*, **137**, 685 (1998).
2. S. N. Pandeya, D. Sriram, G. Nath and E. De Clercq, *Indian. J. Pharm. Sci.*, **61**, 358 (1999).
3. S. N. Pandeya, D. Sriram, G. Nath, and E. De Clercq, *Pharmaceutics Acta Helvetiae*, **74**, 11 (1999).
4. S. N. Pandeya, D. Sriram, G. Nath and E. De Clercq, *Arzeniem, Forsh./Drug Res.*, **50**, 55 (2000).
5. S. N. Pandeya, D. Sriram, G. Nath and E. De Clercq, *Eur. J. Med. Chem.*, **35**, 1 (2000).
6. P. Schewacechter, K. Gutsche, W. Kohimann and G. Kroemer, *Ger. offen. DES*, 120.620. *Chem. Abs.*, 1983, 98, F198267 g.
7. A. Bany, in "Antibiotics in Laboratory Medicine", 5<sup>th</sup> Edn., William and Wilkins, Balmitore, (1991), p. 1.

*Accepted : 23.1.04*